Dow Up0.16% Nasdaq Down0.02%

Avanir Pharmaceuticals, Inc. (AVNR)

-NasdaqGS
5.72 Down 0.09(1.55%) 11:07AM EDT - Nasdaq Real Time Price
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingSep 30, 2013Sep 30, 2012Sep 30, 2011
Total Revenue 75,366   41,275   10,496  
Cost of Revenue4,150  2,120  446  
Gross Profit 71,216   39,155   10,050  
Operating Expenses
Research Development49,506  23,066  15,254  
Selling General and Administrative93,137  74,491  55,426  
Non Recurring -   -   -  
Others -   -   -  
Total Operating Expenses -   -   -  
Operating Income or Loss (71,427) (58,402) (60,629)
Income from Continuing Operations
Total Other Income/Expenses Net52  47  1  
Earnings Before Interest And Taxes(71,375)(58,355)(60,628)
Interest Expense4,098  1,385   -  
Income Before Tax(75,473)(59,741)(60,628)
Income Tax Expense3  3  3  
Minority Interest -   -   -  
Net Income From Continuing Ops(75,476)(59,744)(60,632)
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (75,476) (59,744) (60,632)
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (75,476) (59,744) (60,632)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.